Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Dual inhibition of BCL2 and MCL1, using the small molecule inhibitors venetoclax and S63845, can lead to sustained and durable…
Related Articles
Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics
Kai Rejeski, MD, Ludwig-Maximilians University Hospital, Munich, Germany, discusses non-relapse mortality (NRM) in patients receiving CAR T-cells and bispecific antibodies. He highlights that while cytokine…
Welcome! You are invited to join a webinar: Post-EHA 2025 MDS highlights webinar. After registering, you will receive a confirmation email about joining the webinar.
Join us to watch leading MDS experts present summaries on the most significant abstracts from EHA 2025 followed by interactive panel discussions debating current clinical…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
The evolution of SCT in Hodgkin lymphoma with the introduction of BV and checkpoint inhibitors
Ali Bazarbachi, MD, PhD, American University of Beirut, Beirut, Lebanon, comments on the evolution of stem cell transplantation (SCT) for Hodgkin lymphoma (HL) with the…
Highlights from iwCAR-T 2025: improving the efficacy and safety of CAR T-cells & access in the community
Today’s VJHemOnc podcast features discussions from the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, which was held recently…
T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions
In this discussion, David G. Maloney, MD, PhD, Fred Hutchinson Cancer Center, Seattle, WA, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, and Mazyar…
VEXAS syndrome and MDS: exploring biology, challenges, and treatment
VJHemOnc is pleased to share a feature article that explores the biology and challenges of VEXAS syndrome.
Practical considerations for GPRC5D-directed therapies in multiple myeloma
VJHemOnc is thrilled to bring you this feature covering practical considerations with the use of GPRC5D-directed agents. Hear from leading experts on the value of…
The treatment of R/R large B-cell lymphoma in the second-line setting in the UK
Chris Fox, MBChB(Hons), MRCP, FRCPath, Nottingham University Hospitals NHS Trust – City Campus, Nottingham, UK, comments on the management of patients with relapsed/refractory (R/R) large…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…